New Discovered Alzheimer's Drug Can Expand Life, Slow Memory Loss in Mouse Model

• comments
• 
• 

New research has claimed that Alzheimer's disease can be treated with their new drug. The International team of scientist have announced how to fight it and restore memory loss.

Alzheimer's Association released an estimated people and there are 47 million of a patient who has been diagnosed with this illness. This condition is a neurodegenerative disease that causes serious dementia.

Andrew Tobin, professor of molecular biology at the University of Glasgow said in his statement on how they have treated a mice with their newly discovered drug. This drug is not only responsible for improving symptoms of brain degeneration like cognitive decline however it could help to extend a life-span with sick mice.

According to Voa News, the drug has called as allosteric ligands that target a protein to complexes with memory. When the patient's condition worsen, hippocampus or also known as the protein in a brain region become inactive but the drug performs to initiate the protein which they called M1 muscarinic receptor.

Meanwhile, even if Professor Toben have clearly made his statement, still there are underlying questions remaining in their working place. Some doubt, such as the mechanism or biochemical mechanism in the drug on how it response and made them continually working on.

But the researchers give no assurance to societies that Alzheimer disease can be cured while living only a limited option. The fact is they only focuses on a treatment that lessens the symptoms, according to Eurekalert.

The method was tested in a mouse model of Alzheimer's which raise to show indication of mad cow disease that is similar to humans terms of memory loss, advancement, and death. In a test they've conducted, the untreated mice did not remember any electric shock while the treated one did recall the stimulus.

Professor Tobin gives a caution that the drug only lasts up to 5 to ten years. While the treatments will correspond with side effect who limit the patient submission.